Gland Pharma stock | 2026 rating, price & analyst opinions

Gland Pharma

NSEI:GLAND

Rp 1.710,50

Rp0,00 (0,00%)

1.710,50 Rp

Rp0,00 (0,00%)

End-of-day quote: 03/27/2026

Gland Pharma Stock Value

The current analyst recommendation for NSEI:GLAND is: Hold.

Hold

Gland Pharma Company Info

EPS Growth 5Y

-9,42%

Market Cap

Rp281,82 B

Long-Term Debt

Rp0,78 B

Annual earnings

05/20/2026 (E)

Dividend

Rp17,96

Dividend Yield

1,05%

Founded

1978

Industry

Health Care

Country

India

Website

Gland Pharma

ISIN Number

INE068V01023

Website

http://www.glandpharma.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Rp2.000,00

16.92%

Last Update: 03/28/2026

Analysts: 13

Highest Price Target Rp2.500,00

Average Price Target Rp2.000,00

Lowest Price Target Rp1.525,00

In the last five quarters, Gland Pharma’s Price Target has fallen from Rp1.671,06 to Rp1.649,00 - a -1,32% decrease. Twelve analysts predict that Gland Pharma’s share price will increase in the coming year, reaching Rp2.000,00. This would represent an increase of 16,92%.

Top growth stocks in the health care sector (5Y.)

What does Gland Pharma do?

Gland Pharma Limited (Gland Pharma) specializes in the development, manufacture, and commercialization of injectable pharmaceuticals. The company provides products that cater to a variety of therapeutic areas, leveraging its advanced manufacturing capabilities and strong research and development initiatives. Business Segments Gland Pharma operates primarily in the injectable pharmaceuticals sector, diversifying its operations across multiple therapeutic areas. The company’s segments can be cat...

Business Segments

Gland Pharma operates primarily in the injectable pharmaceuticals sector, diversifying its operations across multiple therapeutic areas. The company’s segments can be categorized based on the types of products developed, focusing on generic and branded medications, along with specialized formulations.

The injectable segment stands out as a critical area, where Gland Pharma engages in the production of a wide range of sterile injectables spanning various medical fields, including oncology, anesthesia, and anti-infectives. Each product reflects the company’s commitment to adhering to exacting quality standards, alongside continuous improvement methodologies aimed at enhancing product performance and safety.

Additionally, Gland Pharma has invested significantly in research and development, which positions it favorably within competitive markets. These investments facilitate innovation, yielding an expanding pipeline of injectable therapies designed to meet current and anticipated medical needs. Strategic partnerships with global pharmaceutical companies amplify these efforts, providing access to advanced technologies and diverse markets.

Business Strategy

Gland Pharma's business strategy emphasizes sustainable growth through innovation, operational efficiency, and geographic expansion. The company aims to develop a diverse product portfolio to mitigate risks associated with market fluctuations while leveraging state-of-the-art manufacturing technologies to enhance productivity.

The company wisely allocates resources to bolster manufacturing capabilities, focusing on creating a pipeline of high-quality products that cater to emerging market needs. Additionally, Gland Pharma is dedicated to expanding its geographic reach, which is pivotal for driving growth in new markets while maintaining a foothold in established regions.

Another critical aspect of Gland Pharma’s strategy is building and nurturing long-term relationships with clients, suppliers, and industry stakeholders. This B2B model positions the company to secure substantial orders that generate consistent revenue streams, thereby improving overall cash flow and operational reliability.

Investment in research and development remains a priority. This commitment not only facilitates the introduction of innovative products but also enhances the company’s competitive edge within the pharmaceutical sector. Close monitoring of industry trends and scientific advancements ensures that Gland Pharma remains aligned with evolving healthcare needs and maintains its leadership in the market.

Products and Services

Gland Pharma's product offerings encompass a wide range of injectable pharmaceuticals, focusing on generic and specialty medications. The company produces sterile injectables that address various therapeutic areas, including but not limited to oncology, anesthetics, anti-infective agents, and cardiovascular disease treatments.

A significant portion of Gland Pharma's portfolio consists of high-demand medicines that comply with international safety and quality standards. The comprehensive product range includes prefilled syringes, vials, and ampoules, ensuring flexibility in meeting diverse patient needs and healthcare provider requirements.

Gland Pharma’s services extend beyond merely developing and manufacturing products. The company is committed to providing extensive customer support, which includes assisting healthcare professionals with product information, usage guidelines, and other relevant resources to enhance patient care.

Furthermore, Gland Pharma is invested in continuous improvement methodologies related to both product and service delivery. The integration of advanced technologies and automation into manufacturing processes enhances efficiency, ensuring swift product availability in response to market demands.

Geographical Markets Served

Gland Pharma operates in numerous geographical markets globally, particularly in the United States, Europe, and various emerging markets. The company's strategic expansions target regions with significant opportunities for growth, allowing the company to tap into diverse customer bases while adapting to regional healthcare needs.

Seasonality

The demand for its injectable products typically remains stable throughout the year. However, certain therapeutic areas may experience fluctuations in demand based on seasonal health trends or market dynamics. The company's diverse product portfolio mitigates the impact of any potential seasonality, ensuring consistent revenue flow.

Customers

Gland Pharma serves a broad customer base that includes healthcare providers, pharmacies, hospitals, and pharmaceutical distributors across various geographies. The company’s commitment to delivering high-quality injectable products has built strong relationships with numerous healthcare professionals and institutions.

Modes of Sales and Marketing

Gland Pharma utilizes a diverse approach to sales and marketing, combining direct engagement with healthcare professionals, leveraging digital marketing platforms, and participating in industry conferences and seminars. The company emphasizes building long-term relationships with customers through effective communication, product demonstrations, and educational outreach.

Distribution channels encompass a range of options, including partnerships with pharmaceutical distributors, direct supply to hospitals, and integration into pharmacy networks. The effective utilization of these channels ensures that Gland Pharma products reach end-users efficiently, thereby enhancing overall sales performance.

History

Gland Pharma Limited was founded in 1978. The company was incorporated in 1978.

Gland Pharma Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Industry:** 100% **Top 3 Markets:** 1. **USA:** approximately 60% 2. **India:** approximately 15% 3. **Europe:** approximately 10% Gland Pharma Limited generates its revenues entirely from the pharmaceutical industry, with a focus on the manufacturing and distribution of...

At which locations are the company’s products manufactured?

**Production Sites:** Hyderabad, India Gland Pharma Limited mainly produces its products in Hyderabad, India. The city is a significant hub for the pharmaceutical industry and offers a well-developed infrastructure as well as access to qualified personnel. The company operates several production f...

What strategy does Gland Pharma pursue for future growth?

**Revenue Growth:** Estimated 10-12% annually (2026) **Focus on International Markets:** Expansion in the USA and Europe Gland Pharma Limited pursues a growth strategy that is strongly focused on geographical expansion and diversification of the product portfolio. The company plans to further expan...

Which raw materials are imported and from which countries?

**Main raw materials:** Active pharmaceutical ingredients (APIs), excipients, packaging materials **Countries of origin:** China, USA, Europe Gland Pharma Limited mainly imports active pharmaceutical ingredients (APIs) that are crucial for the production of their products. A significant portion of...

How strong is the company’s competitive advantage?

**Market Share:** 5% in the Indian pharmaceutical market (2025, estimated) **R&D Expenses:** 7% of revenue (2025) **EBITDA Margin:** 30% (2025) Gland Pharma Limited has a solid competitive advantage in the Indian pharmaceutical market, particularly due to its specialization in injectable me...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 45% (estimated for 2026) **Insider Buys/Sells:** No significant transactions in the last year (estimated for 2026) The institutional investor share in Gland Pharma Limited is estimated to be 45%. This demonstrates the confidence of institutional investors in the c...

What percentage market share does Gland Pharma have?

**Market share of Gland Pharma Limited:** Estimated 4% (2026) **Top competitors and their market shares:** 1. Sun Pharmaceutical Industries Ltd.: 10% 2. Dr. Reddy's Laboratories: 8% 3. Cipla Ltd.: 7% 4. Aurobindo Pharma Ltd.: 6% 5. Lupin Ltd.: 5% 6. Gland Pharma Limited: 4% 7. Biocon Ltd.: 3%...

Is Gland Pharma stock currently a good investment?

**Revenue Growth:** 10% (2025) **Profit Growth:** 8% (2025) **Research and Development Expenses:** 15% of Revenue (2025) Gland Pharma Limited recorded solid revenue growth of 10% in 2025, attributed to strong demand for its pharmaceutical products and successful market expansion. Profit growth stan...

Does Gland Pharma pay a dividend – and how reliable is the payout?

**Dividend yield:** 1.5% (estimated for 2026) **Dividend history:** Regular payouts in recent years Gland Pharma Limited has regularly distributed dividends in recent years, indicating a certain level of reliability. The estimated dividend yield for 2026 is around 1.5%, which is moderate compared...

New support ticket

Explore

Gland Pharma Stock Value

Gland Pharma Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Gland Pharma do?

Gland Pharma Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Gland Pharma Stock Value

Gland Pharma Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Gland Pharma do?

Gland Pharma Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.